Asarina Pharma AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB. The Company has entered into… Read More »Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB
Bolaget meddelar idag att man byter Certified Adviser från Erik Penser Bank AB till Carnegie Investment Bank AB (publ). Bolaget har ingått avtal med Carnegie… Read More »Asarina Pharma AB byter Certified Adviser till Carnegie Investment Bank AB (publ)
Stockholm, 16 november 2023. Asarina Pharma AB (publ., "Asarina" eller "Bolaget") ger idag en uppdatering om sina partneraktiviteter och finansiella status relaterat till sitt primära… Read More »Asarina Pharma uppdaterar om partnering aktiviteter och finansiella frågor
Stockholm, 16 November 2023. Asarina Pharma AB (publ., “Asarina” or “the Company”) today provides an update on its partnering activities and financial status related to… Read More »Asarina Pharma updates on partnering and financials
Consultant Neurologist Dr. Heidi Biernat, Head of the Tourette Clinic at Copenhagen’s Bispebjerg University Hospital and Principal Investigator in Asarina Pharma’s Phase IIa study in… Read More »Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders
Asarina Pharma AB (publ) (”Bolaget”) avhöll den 22 maj 2023 årsstämma i Fredersen Advokatbyrås lokaler på Birger Jarlsgatan 8 i Stockholm. Vid stämman fattades bland… Read More »Kommuniké från årsstämma i Asarina Pharma AB (publ)
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on 22 May 2023 at Fredersen… Read More »Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
Aktieägarna i Asarina Pharma AB (publ), org.nr 556698-0750, (”Bolaget”) kallas härmed till årsstämma den 22 maj 2023 kl. 10:00 i Fredersen Advokatbyrås lokaler på Birger… Read More »KALLELSE TILL ÅRSSTÄMMA I ASARINA PHARMA AB (PUBL)
The shareholders of Asarina Pharma AB (publ) reg. no. 556698-0750 (the “Company”) are hereby summoned to attend the Annual General Meeting (the “AGM”) on 22… Read More »NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)
(Stockholm, 1 april 2023.) Asarina Pharma publicerar idag resultat från sin fas IIa-studie av den endogena neurosteroiden Sepranolon för behandling av Tourette syndrom. Studiens primära… Read More »Asarina Pharma publicerar positiva resultat från sin fas IIa-studie av Sepranolon i Tourette syndrom